These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15265053)

  • 1. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.
    Iovino M; Feifel U; Yong CL; Wolters JM; Wallenstein G
    Cephalalgia; 2004 Aug; 24(8):645-56. PubMed ID: 15265053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists.
    Trocóniz IF; Wolters JM; Schaefer HG; Roth W
    Eur J Pharm Sci; 2004 Jul; 22(4):287-95. PubMed ID: 15196585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
    Olesen J; Diener HC; Husstedt IW; Goadsby PJ; Hall D; Meier U; Pollentier S; Lesko LM;
    N Engl J Med; 2004 Mar; 350(11):1104-10. PubMed ID: 15014183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.
    Trocóniz IF; Wolters JM; Tillmann C; Schaefer HG; Roth W
    Clin Pharmacokinet; 2006; 45(7):715-28. PubMed ID: 16802852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1.
    Hay DL; Christopoulos G; Christopoulos A; Sexton PM
    Mol Pharmacol; 2006 Dec; 70(6):1984-91. PubMed ID: 16959943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats.
    Arulmani U; Schuijt MP; Heiligers JP; Willems EW; Villalón CM; Saxena PR
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):291-7. PubMed ID: 15228501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig.
    Kapoor K; Arulmani U; Heiligers JP; Willems EW; Doods H; Villalón CM; Saxena PR
    Eur J Pharmacol; 2003 Aug; 475(1-3):69-77. PubMed ID: 12954361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
    Swaisland H; Laight A; Stafford L; Jones H; Morris C; Dane A; Yates R
    Clin Pharmacokinet; 2001; 40(4):297-306. PubMed ID: 11368294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.